Alumis Inc. unveils late-stage immunology pipeline and key upcoming clinical milestones

Reuters12-04

<a href="https://laohu8.com/S/ALMS">Alumis Inc.</a> unveils late-stage immunology pipeline and key upcoming clinical milestones

Alumis Inc. has released a corporate presentation highlighting progress in its late-stage precision immunology pipeline. The company's portfolio includes three clinical-stage molecules: Envudeucitinib, a TYK2 inhibitor for psoriasis and systemic lupus erythematosus $(SLE)$; A-005, a CNS-penetrant TYK2 inhibitor for multiple sclerosis and other neuroinflammatory diseases; and Lonigutamab, an anti-IGF-1R therapy for thyroid eye disease. Top-line Phase 3 data for Envudeucitinib in psoriasis are expected in early Q1 2026, with Phase 2b data in SLE anticipated in Q3 2026. The presentation notes that the company had $377.7 million in cash, cash equivalents, and marketable securities as of September 30, 2025, projected to fund operations into 2027. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief on December 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588257040?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 02:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588257040","market":"nz","top_or_hot":-1,"title":"Alumis Inc. unveils late-stage immunology pipeline and key upcoming clinical milestones","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ALMS\">Alumis Inc.</a> unveils late-stage immunology pipeline and key upcoming clinical milestones\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alumis Inc. has released a corporate presentation highlighting progress in its late-stage precision immunology pipeline. The company's portfolio includes three clinical-stage molecules: Envudeucitinib, a TYK2 inhibitor for psoriasis and systemic lupus erythematosus <a href=\"https://laohu8.com/S/SLE\">$(SLE)$</a>; A-005, a CNS-penetrant TYK2 inhibitor for multiple sclerosis and other neuroinflammatory diseases; and Lonigutamab, an anti-IGF-1R therapy for thyroid eye disease. Top-line Phase 3 data for Envudeucitinib in psoriasis are expected in early Q1 2026, with Phase 2b data in SLE anticipated in Q3 2026. The presentation notes that the company had $377.7 million in cash, cash equivalents, and marketable securities as of September 30, 2025, projected to fund operations into 2027. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief on December 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alumis Inc. unveils late-stage immunology pipeline and key upcoming clinical milestones</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlumis Inc. unveils late-stage immunology pipeline and key upcoming clinical milestones\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-04 02:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ALMS\">Alumis Inc.</a> unveils late-stage immunology pipeline and key upcoming clinical milestones\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alumis Inc. has released a corporate presentation highlighting progress in its late-stage precision immunology pipeline. The company's portfolio includes three clinical-stage molecules: Envudeucitinib, a TYK2 inhibitor for psoriasis and systemic lupus erythematosus <a href=\"https://laohu8.com/S/SLE\">$(SLE)$</a>; A-005, a CNS-penetrant TYK2 inhibitor for multiple sclerosis and other neuroinflammatory diseases; and Lonigutamab, an anti-IGF-1R therapy for thyroid eye disease. Top-line Phase 3 data for Envudeucitinib in psoriasis are expected in early Q1 2026, with Phase 2b data in SLE anticipated in Q3 2026. The presentation notes that the company had $377.7 million in cash, cash equivalents, and marketable securities as of September 30, 2025, projected to fund operations into 2027. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief on December 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALMS","symbol_name":"Alumis Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL7MC5D8:1","article_id":"2588257040","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588257040","pubTimestamp":1764786451,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alumis Inc. has released a corporate presentation highlighting progress in its late-stage precision immunology pipeline. The company's portfolio includes three clinical-stage molecules: Envudeucitinib, a TYK2 inhibitor for psoriasis and systemic lupus erythematosus ; A-005, a CNS-penetrant TYK2 inhibitor for multiple sclerosis and other neuroinflammatory diseases; and Lonigutamab, an anti-IGF-1R therapy for thyroid eye disease. Top-line Phase 3 data for Envudeucitinib in psoriasis are expected in early Q1 2026, with Phase 2b data in SLE anticipated in Q3 2026. The presentation notes that the company had $377.7 million in cash, cash equivalents, and marketable securities as of September 30, 2025, projected to fund operations into 2027. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALMS":"Alumis Inc.","BK4007":"制药"},"translate_title":"Alumis Inc.公布后期免疫学管道和即将到来的关键临床里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALMS":0.9},"content_text":"Alumis Inc. unveils late-stage immunology pipeline and key upcoming clinical milestones\n    \n\n        Alumis Inc. has released a corporate presentation highlighting progress in its late-stage precision immunology pipeline. The company's portfolio includes three clinical-stage molecules: Envudeucitinib, a TYK2 inhibitor for psoriasis and systemic lupus erythematosus $(SLE)$; A-005, a CNS-penetrant TYK2 inhibitor for multiple sclerosis and other neuroinflammatory diseases; and Lonigutamab, an anti-IGF-1R therapy for thyroid eye disease. Top-line Phase 3 data for Envudeucitinib in psoriasis are expected in early Q1 2026, with Phase 2b data in SLE anticipated in Q3 2026. The presentation notes that the company had $377.7 million in cash, cash equivalents, and marketable securities as of September 30, 2025, projected to fund operations into 2027. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief on December 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588257040","isCrawlerRequest":true}